Relypsa, Inc.
12
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
16.7%
2 terminated/withdrawn out of 12 trials
83.3%
-3.2% vs industry average
33%
4 trials in Phase 3/4
90%
9 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
An Intensive Lifestyle Intervention Program in CKD (Move to Health 2)
Role: collaborator
Pragmatic Trial Of Alerts for Use of Mineralocorticoid Receptor Antagonists
Role: collaborator
Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-On
Role: collaborator
A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)
Role: lead
Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)
Role: lead
Evaluation of Patiromer in Heart Failure Patients
Role: lead
Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease
Role: lead
An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis
Role: lead
Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease
Role: lead
Patiromer With or Without Food for the Treatment of Hyperkalemia
Role: lead
Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)
Role: collaborator
High-dose Aldosterone Antagonist for Acute Decompensated Heart Failure
Role: collaborator
All 12 trials loaded